Type of Cancer: NSCLC
Sponsor: BMS
Phase / Design: Phase 3 Randomized Open label
Population: Locally advanced: Stage IIIA, IIIB, or IIIC Unresectable Amenable to Chemoradiotherapy Naïve EGFR mutation (-)
